Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)
- Authors:
- Zexin Fu
- Jinlei Zhou
- Rui Chen
- Yihua Jin
- Ting Ni
- Lingbo Qian
- Chi Xiao
-
Affiliations: School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang 310053, P.R. China - Published online on: July 22, 2020 https://doi.org/10.3892/ol.2020.11897
- Article Number: 36
-
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Katz AJ, Chia VM, Schoonen WM and Kelsh MA: Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 26:1627–1642. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Noone AM HN, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Bethesda, MD: based on November 2017 SEER data submission, posted to the SEER web site. April. 2018 | |
|
Inaba H, Greaves M and Mullighan CG: Acute lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pui CH, Nichols KE and Yang JJ: Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol. 16:227–240. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hunger SP and Mullighan CG: Acute lymphoblastic leukemia in children. N Engl J Med. 373:1541–1552. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maude SL, Noelle F, Shaw PA, Richard A, Barrett DM, Bunin NJ, Anne C, Gonzalez VE, Zhaohui Z, Lacey SF, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Geabanacloche JC, Pavletic SZ, Hickstein DD, Lu TL, et al: Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 34:1112–1121. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, et al: Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 126:3363–3376. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gardner R, Wu D, Cherian S, Fang M, Hanafi L, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG and Turtle CJ: Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy. Blood. 127:2406–2410. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al: CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 126:2123–2138. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al: CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 24:20–28. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fuerst ML: CD22 CAR T-Cell therapy induces remissions in young ALL patients. Oncol Times. 39:352017. View Article : Google Scholar | |
|
Prasad V: Immunotherapy: Tisagenlecleucel-the first approved CAR-T-cell therapy: Implications for payers and policy makers. Nat Rev Clin Oncol. 15:11–12. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ma F, Ho JY, Du H, Xuan F, Wu X, Wang Q, Wang L, Liu Y, Ba M, Wang Y, et al: Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Hematol Oncol. 37:601–608. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, Dai H, Yu C, Sun Q, Qiao J, et al: Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. J Hematol Oncol. 9:1312016. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Zhang J, Wang M, Fu G, Li Y, Pei L, Xiong Z, Qin D, Zhang R, Tian X, et al: Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Br J Haematol. 181:360–371. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, Huang X, Wu S, Shao D, Deng C, et al: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 11:252018. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao X, Yuan T, Meng JX, Jiang YY, Cao YQ, Li Q, Sun R and Zhao MF: Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells. Zhonghua Yi Xue Za Zhi. 100:593–598. 2020.(In Chinese). PubMed/NCBI | |
|
Zhang J, Yang F, Qiu HY, Wu Q, Kong DQ, Zhou J, Han Y and Wu DP: Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: Report of three cases. Leuk Lymphoma. 60:1454–1461. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Irina M, Maryalice SS, Phan GQ, Hughes MS, Sherry RM, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119:2709–2720. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z, Barrett DM, Grupp SA and Milone MC: High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol Res. 6:36–46. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Curran KJ, Pegram HJ and Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med. 14:405–415. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dai H, Wang Y, Lu X and Han W: Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 108:djv4392016. View Article : Google Scholar : PubMed/NCBI | |
|
Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M and Kobold S: Teaching an old dog new tricks: Next-generation CAR T cells. B J Cancer. 120:26–37. 2019. View Article : Google Scholar | |
|
Kenderian SS, Ruella M, Gill S and Kalos M: Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res. 74:6383–6389. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chmielewski M, Kopecky C, Hombach AA and Abken H: IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71:5697–5706. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Scheuermann RH and Racila E: CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy. Leuk Lymphoma. 18:385–397. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Abate-Daga D and Davila ML: CAR models: Next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics. 3:160142016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 385:517–528. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, et al: Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 129:3322–3331. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zuo YX, Jia YP, Wu J, Wang JB, Lu AD, Dong LJ, Chang LJ and Zhang LP: Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: Long term follow-up outcomes. Zhonghua Xue Ye Xue Za Zhi. 40:270–275. 2019.(In Chinese). PubMed/NCBI | |
|
Barba P, Sampol A, Calbacho M, Gonzalez J, Serrano J, Martínez-Sánchez P, Fernández P, García-Boyero R, Bueno J and Ribera JM: Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Am J Hematol. 87:631–634. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Zhang X and Chen XH: Interleukin-2 priming chemotherapy: A strategy to improve the remission of refractory/relapsed T cell acute lymphoblastic leukemia. Med Hypotheses. 81:878–880. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan RA, Gray D, Lomova A and Kohn DB: Hematopoietic stem cell gene therapy: Progress and lessons learned. Cell Stem Cell. 21:574–590. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Maus MV, Grupp SA, Porter DL and June CH: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 123:2625–2635. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, et al: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 16:45–63. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sermer D and Brentjens R: CAR T-cell therapy: Full speed ahead. Hematol Oncol. 37 (Suppl 1):S95–S100. 2019. View Article : Google Scholar | |
|
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al: Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 6:224ra2252014. View Article : Google Scholar | |
|
Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, et al: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 24:739–748. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al: Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol. 15:47–62. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, Liang B, Luo Y, Shi J, Jin A, et al: Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 9:702016. View Article : Google Scholar : PubMed/NCBI | |
|
Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al: Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7:1404–1419. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, Appelbaum J and Maloney DG: Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 12:195–205. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chavez JC, Jain MD and Kharfan-Dabaja MA: Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Hematol Oncol Stem Cell Ther. 13:1–6. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 25:625–638. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Traube C, Silver G, Kearney J, Patel A, Atkinson TM, Yoon MJ, Halpert S, Augenstein J, Sickles LE, Li C and Greenwald B: Cornell Assessment of Pediatric Delirium: A valid, rapid, observational tool for screening delirium in the PICU*. Crit Care Med. 42:656–663. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Silver G, Kearney J, Traube C and Hertzig M: Delirium screening anchored in child development: The Cornell Assessment for Pediatric Delirium. Palliat Support Care. 13:1005–1011. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hombach AA and Abken H: Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells? Expert Rev Clin Immunol. 13:151–155. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hucks G and Rheingold SR: The journey to CAR T cell therapy: The pediatric and young adult experience with relapsed or refractory B-ALL. Blood Cancer J. 9:102019. View Article : Google Scholar : PubMed/NCBI | |
|
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 7:303ra1392015. View Article : Google Scholar : PubMed/NCBI | |
|
Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, et al: Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 139:S1–S46. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, Futrell RB, Orentas RJ, Li D, Gardner RA and Jensen MC: CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 129:2123–2132. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bonifant CL, Jackson HJ, Brentjens RJ and Curran KJ: Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 3:160112016. View Article : Google Scholar : PubMed/NCBI | |
|
Zah E, Lin MY, Silva-Benedict A, Jensen MC and Chen YY: T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B Cells. Cancer Immunol Res. 4:498–508. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al: Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 365:1673–1683. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Howard SC, Jones DP and Pui CH: The tumor lysis syndrome. N Engl J Med. 364:1844–1854. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Minoia F, Bovis F, Davi S, Insalaco A, Lehmberg K, Shenoi S, Weitzman S, Espada G, Gao YJ, Anton J, et al: Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome. J Pediatr. 189:72–78.e3. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Wu Z, Liu Y and Han W: New development in CAR-T cell therapy. J Hematol Oncol. 10:532017. View Article : Google Scholar : PubMed/NCBI | |
|
Ruella M and Maus MV: Catch me if you can: Leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 14:357–362. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL, Liu SH, et al: High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 31:2587–2593. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, et al: Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5:1282–1295. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, et al: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 24:1499–1503. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368:1509–1518. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mejstríková E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM, Zugmaier G, Gore L, von Stackelberg A and Locatelli F: CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 7:6592017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S and Li Y: Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 10:26642019. View Article : Google Scholar : PubMed/NCBI | |
|
Maude SL, Teachey DT, Rheingold SR, Shaw PA, Aplenc R, Barrett DM, Barker CS, Callahan C, Frey NV, Nazimuddin F, et al: Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J Clin Oncol. 34:30112016. View Article : Google Scholar | |
|
Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, et al: Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 24:1504–1506. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, et al: CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 568:112–116. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zolov SN, Rietberg SP and Bonifant CL: Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy. 20:1259–1266. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zou F, Lu L, Liu J, Xia B, Zhang W, Hu Q, Liu W, Zhang Y, Lin Y, Jing S, et al: Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nat Commun. 10:41092019. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng S, Asnani M and Thomas-Tikhonenko A: Escape from all-CARTaz: Leukemia immunoediting in the age of chimeric antigen receptors. Cancer J. 25:217–222. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cho FN, Chang TH, Shu CW, Ko MC, Liao SK, Wu KH, Yu MS, Lin SJ, Hong YC, Chen CH, et al: Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis. PLoS One. 9:e1093522014. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, Wu Y, Zhou F, Ai L, Shi W, et al: Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol. 94:1113–1122. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider D, Xiong Y, Wu D, Nlle V, Schmitz S, Haso W, Kaiser A, Dropulic B and Orentas RJ: A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer. 5:422017. View Article : Google Scholar : PubMed/NCBI | |
|
Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, et al: Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 126:3814–3826. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH and Gill S: Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia. 31:246–248. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dolnikov A, Shen S, Klamer G, Joshi S, Xu N, Yang L, Micklethwaite K and O'Brien TA: Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia. Exp Hematol. 43:1001–1014.e5. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK and Binder G: Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 25:176–191. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Jiang H, Luo H, Sun Y, Shi B, Sun R and Li Z: An IL-4/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment. Front Immunol. 10:16912019. View Article : Google Scholar : PubMed/NCBI | |
|
Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM and Ramos CA: Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 125:3905–3916. 2015. View Article : Google Scholar : PubMed/NCBI |
